NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 201 filers reported holding NOVOCURE LTD in Q1 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $425,000 | +2.2% | 5,195 | -6.8% | 0.00% | 0.0% |
| Q3 2019 | $416,000 | +292.5% | 5,577 | +227.7% | 0.00% | +200.0% |
| Q2 2019 | $106,000 | +65.6% | 1,702 | +27.9% | 0.00% | – |
| Q1 2019 | $64,000 | +93.9% | 1,331 | +35.5% | 0.00% | – |
| Q4 2018 | $33,000 | +312.5% | 982 | +586.7% | 0.00% | – |
| Q3 2018 | $8,000 | +700.0% | 143 | +297.2% | 0.00% | – |
| Q2 2018 | $1,000 | 0.0% | 36 | 0.0% | 0.00% | – |
| Q1 2018 | $1,000 | 0.0% | 36 | 0.0% | 0.00% | – |
| Q4 2017 | $1,000 | -97.6% | 36 | -98.2% | 0.00% | – |
| Q3 2017 | $41,000 | +355.6% | 2,036 | +279.9% | 0.00% | – |
| Q2 2017 | $9,000 | +125.0% | 536 | 0.0% | 0.00% | – |
| Q1 2017 | $4,000 | -60.0% | 536 | -58.3% | 0.00% | – |
| Q4 2016 | $10,000 | +42.9% | 1,286 | +63.6% | 0.00% | – |
| Q3 2016 | $7,000 | -22.2% | 786 | +4.8% | 0.00% | – |
| Q2 2016 | $9,000 | -55.0% | 750 | -46.4% | 0.00% | – |
| Q1 2016 | $20,000 | -35.5% | 1,400 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $31,000 | – | 1,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |